rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
Status:
Unknown status
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This is multicenter, open-label, randomized, active-controled, phase IV study of local direct
intra-tumor injection of rAd-p53 monotherapy, with concurrent radioactive iodine , or
combination with surgery for treatment of advanced malignant thyroid tumors.